Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 41, 211–218 (2016).
Boschert, V., Teusch, J., Müller-Richter, U. D. A., Brands, R. C. & Hartmann, S. PKM2 modulation in head and neck squamous cell carcinoma. Int. J. Mol. Sci. 23, 775 (2022).
Paul, S., Ghosh, S. & Kumar, S. Tumor glycolysis, an essential sweet tooth of tumor cells. Semin. Cancer Biol. 86, 1216–1230 (2022).
Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441–464 (2011).
Devic, S. Warburg effect—a consequence or the cause of carcinogenesis? J. Cancer 7, 817–822 (2016).
González-Moles, M., Keim-Del Pino, C. & Ramos-García, P. Hallmarks of cancer expression in oral lichen planus: a scoping review of systematic reviews and meta-analyses. Int. J. Mol. Sci. 23, 13099 (2022).
Guak, H. et al. PGC-1β maintains mitochondrial metabolism and restrains inflammatory gene expression. Sci. Rep. 12, 16028 (2022).
Li, Y. et al. PGC-1α participates in tumor chemoresistance by regulating glucose metabolism and mitochondrial function. Mol. Cell Biochem. 478, 47–57 (2022).
Wang, H. et al. PGC-1 alpha regulates mitochondrial biogenesis to ameliorate hypoxia-inhibited cementoblast mineralization. Ann. N. Y Acad. Sci. 1516, 300–311 (2022).
Fang, X. Q. et al. PGC1α cooperates with FOXA1 to regulate epithelial mesenchymal transition through the TCF4-TWIST1. Int J. Mol. Sci. 23, 8247 (2022).
Schmid, S. et al. PGC-1β modulates catabolism and fiber atrophy in the fasting-response of specific skeletal muscle beds. Mol. Metab. 66, 101643 (2022).
Luo, X. et al. Posttranslational regulation of PGC-1α and its implication in cancer metabolism. Int. J. Cancer 145, 1475–1483 (2019).
Bost, F. & Kaminski, L. The metabolic modulator PGC-1α in cancer. Am. J. Cancer Res. 9, 198–211 (2019).
Yun, S. H., Han, S. H. & Park, J. I. Peroxisome proliferator-activated receptor γ and PGC-1α in cancer: dual actions as tumor promoter and suppressor. PPAR Res. 2018, 6727421 (2018).
Liu, C. L. et al. PGC1α downregulation and glycolytic phenotype in thyroid cancer. J. Cancer 10, 3819–3829 (2019).
Zuo, Q. et al. PPARγ coactivator-1α suppresses metastasis of hepatocellular carcinoma by inhibiting Warburg effect by PPARγ-dependent WNT/β-catenin/pyruvate dehydrogenase kinase isozyme 1 axis. Hepatology 73, 644–660 (2021).
Torrano, V. et al. The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nat. Cell Biol. 18, 645–656 (2016).
Takeda, D. et al. Decreased mitochondrial copy numbers in oral squamous cell carcinoma. Head Neck 38, 1170–1175 (2016).
Mello, F. W. et al. Prevalence of oral potentially malignant disorders: a systematic review and meta-analysis. J. Oral. Pathol. Med. 47, 633–640 (2018).
Teh, M. T. et al. Molecular signatures of tumour and its microenvironment for precise quantitative diagnosis of oral squamous cell carcinoma: an international multi-cohort diagnostic validation study. Cancers 14, 1389 (2022).
Brouns, E. R. et al. Oral leukoplakia classification and staging system with incorporation of differentiated dysplasia. Oral Dis. 00, 1–10 (2022).
Li, C. et al. Autofluorescence imaging as a noninvasive tool of risk stratification for malignant transformation of oral leukoplakia: a follow-up cohort study. Oral. Oncol. 130, 105941 (2022).
Amarasinghe, H. et al. Economic cost of managing patients with oral potentially malignant disorders in Sri Lanka. Community Dent. Oral. Epidemiol. 50, 124–129 (2022).
Sathasivam, H. P. et al. Gene expression changes associated with malignant transformation of oral potentially malignant disorders. J. Oral. Pathol. Med. 50, 60–67 (2021).
Sathasivam, H. P. et al. Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology. Br. J. Cancer 125, 413–421 (2021).
Lin, S. C. & Hardie, D. G. AMPK: sensing glucose as well as cellular energy status. Cell Metab. 27, 299–313 (2018).
Certo, M., Tsai, C. H., Pucino, V., Ho, P. C. & Mauro, C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat. Rev. Immunol. 21, 151–161 (2021).
Mishra, D. & Banerjee, D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment. Cancers 11, 750 (2019).
Niu, D. et al. Lactic acid, a driver of tumor-stroma interactions. Int. Immunopharmacol. 106, 108597 (2022).
Summermatter, S., Santos, G., Pérez-Schindler, J. & Handschin, C. Skeletal muscle PGC-1α controls whole-body lactate homeostasis through estrogen-related receptor α-dependent activation of LDH B and repression of LDH A. Proc. Natl. Acad. Sci. USA 110, 8738–8743 (2013).
LeBleu, V. S. et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 1001–1015 (2014).
Bruns, I. et al. Disruption of peroxisome proliferator-activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells. J. Biol. Chem. 294, 3037–3050 (2019).
Vazquez, F. et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23, 287–301 (2013).
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S. & Baradaran, B. The relation between PI3K/AKT signalling pathway and cancer. Gene 698, 120–128 (2019).
Alzahrani, A. S. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 59, 125–132 (2019).
He, Y. et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 425 (2021).
Rao, J. et al. The key role of PGC-1α in mitochondrial biogenesis and the proliferation of pulmonary artery vascular smooth muscle cells at an early stage of hypoxic exposure. Mol. Cell Biochem. 367, 9–18 (2012).
Shiota, M. et al. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol. Endocrinol. 24, 114–127 (2010).
Wang, L., Yang, M. & Jin, H. PI3K/AKT phosphorylation activates ERRα by upregulating PGC‑1α and PGC‑1β in gallbladder cancer. Mol. Med. Rep. 24, 613 (2021).
Yun, S. H. & Park, J. I. PGC-1α regulates cell proliferation and invasion via AKT/GSK-3β/β-catenin pathway in human colorectal cancer SW620 and SW480 cells. Anticancer Res. 40, 653–664 (2020).
Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer 20, 74–88 (2020).
Lien, E. C., Lyssiotis, C. A. & Cantley, L. C. Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer. Metab. Cancer 207, 39–72 (2016).
Feng, Y. et al. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 7, 6124–6136 (2018).
Shu, D. Y., Butcher, E. R. & Saint-Geniez, M. Suppression of PGC-1α drives metabolic dysfunction in TGFβ2-induced EMT of retinal pigment epithelial cells. Int. J. Mol. Sci. 22, 4701 (2021).
Mohtasham, N. et al. Evaluation of tissue and serum expression levels of lactate dehydrogenase isoenzymes in patients with head and neck squamous cell carcinoma. Anticancer Agents Med. Chem. 19, 2072–2078 (2019).
Bagué, S. et al. Prognostic capacity of the transcriptional expression of lactate dehydrogenase A in patients with head and neck squamous cell carcinoma. Head Neck 44, 2505–2512 (2022).
Cai, H. et al. LDHA promotes oral squamous cell carcinoma progression through facilitating glycolysis and epithelial-mesenchymal transition. Front. Oncol. 9, 1446 (2019).
Grimm, M. et al. Association of cancer metabolism-related proteins with oral carcinogenesis— indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma? J. Transl. Med. 12, 208 (2014).
Yao, F., Zhao, T., Zhong, C., Zhu, J. & Zhao, H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol. 34, 25–31 (2013).
Jiang, F., Ma, S., Xue, Y., Hou, J. & Zhang, Y. LDH-A promotes malignant progression via activation of epithelial-to-mesenchymal transition and conferring stemness in muscle-invasive bladder cancer. Biochem. Biophys. Res. Commun. 469, 985–992 (2016).
Zhao, J. et al. LDHA promotes tumor metastasis by facilitating epithelial‑mesenchymal transition in renal cell carcinoma. Mol. Med. Rep. 16, 8335–8344 (2017).
Cheung, E. C. & Vousden, K. H. The role of ROS in tumour development and progression. Nat. Rev. Cancer 22, 280–297 (2022).
Nakamura, H. & Takada, K. Reactive oxygen species in cancer: current findings and future directions. Cancer Sci. 112, 3945–3952 (2021).
Nourazarian, A. R., Kangari, P. & Salmaninejad, A. Roles of oxidative stress in the development and progression of breast cancer. Asian Pac. J. Cancer Prev. 15, 4745–4751 (2014).
Lenaz, G. Mitochondria and reactive oxygen species. Which role in physiology and pathology? Adv. Exp. Med. Biol. 942, 93–136 (2012).
Rius-Pérez, S., Torres-Cuevas, I., Millán, I., Ortega, Á. L. & Pérez, S. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid. Med. Cell Longev. 2020, 1452696 (2020).
Yang, S. et al. PGC1α is required for the induction of contact inhibition by suppressing ROS. Biochem. Biophys. Res. Commun. 501, 739–744 (2018).
Thirupathi, A. & de Souza, C. T. Multi-regulatory network of ROS: the interconnection of ROS, PGC-1 alpha, and AMPK-SIRT1 during exercise. J. Physiol. Biochem. 73, 487–494 (2017).
Kim, B. et al. PGC1α induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells. Oncotarget 8, 60299–60311 (2017).
Pan, J. S., Hong, M. Z. & Ren, J. L. Reactive oxygen species: a double-edged sword in oncogenesis. World J. Gastroenterol. 15, 1702–1707 (2009).
Aggarwal, V. et al. Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomolecules 9, 735 (2019).
Sarmiento-Salinas, F. L. et al. Reactive oxygen species: role in carcinogenesis, cancer cell signaling and tumor progression. Life Sci. 284, 119942 (2021).
Assi, M. The differential role of reactive oxygen species in early and late stages of cancer. Am. J. Physiol. Regul. Integr. Comp. Physiol. 313, R646–R653 (2017).
Liao, Z., Chua, D. & Tan, N. S. Reactive oxygen species: a volatile driver of field cancerization and metastasis. Mol. Cancer 18, 65 (2019).
Bhatti, J. S., Bhatti, G. K. & Reddy, P. H. Mitochondrial dysfunction and oxidative stress in metabolic disorders—a step towards mitochondria based therapeutic strategies. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 1066–1077 (2017).
Gravel, S. P. Deciphering the dichotomous effects of PGC-1α on tumorigenesis and metastasis. Front. Oncol. 8, 75 (2018).
Sharabi, K. et al. Selective chemical inhibition of PGC-1α gluconeogenic activity ameliorates type 2 diabetes. Cell 169, 148–160.e115 (2017).
Xiang, Y. et al. SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation. Life Sci. 256, 117971 (2020).
Raggi, C. et al. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J. Hepatol. 74, 1373–1385 (2021).
Liu, W., Yang, Y., Zhang, X. & Shi, H. Oral potentially malignant disorder research in Taiwan and mainland China: a scientometric analysis. J. Dent. Sci. 17, 1854–1858 (2022).